MediWound Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
MediWound (MDWD) Tops Q2 EPS by 35c, Revenues Beat
August 13, 2019 7:02 AM EDTMediWound (NASDAQ: MDWD) reported Q2 EPS of $0.32, $0.35 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $20.7 million versus the consensus estimate of $4.45 million.
Business and Financial Highlights for the Second Quarter 2019 and Recent Weeks include:
Total revenues for the second quarter of 2019 were $20.7 million, driven primarily by $17.5 million upfront payment from Vericel for the NexoBrid license; As of June 30, 2019, the Company had $38.7 million in cash and short-term investments, compared to $23.6 million as of December 31, 2018; Entered into an exclusive commercial license and supply agreement with... More